CSIRO Publishing blank image blank image blank image blank imageBooksblank image blank image blank image blank imageJournalsblank image blank image blank image blank imageAbout Usblank image blank image blank image blank imageShopping Cartblank image blank image blank image You are here: Journals > Sexual Health   
Sexual Health
Journal Banner
  Publishing on sexual health from the widest perspective
 
blank image Search
 
blank image blank image
blank image
 
  Advanced Search
   

Journal Home
About the Journal
Editorial Committee
Contacts
Content
Online Early
Current Issue
Just Accepted
All Issues
Online Early
Special Issues
Sample Issue
For Authors
General Information
Instructions to Authors
Submit Article
Open Access
For Referees
Referee Guidelines
Review Article
Annual Referee Index
For Advertisers
For Subscribers
Subscription Prices
Customer Service
Print Publication Dates

blue arrow e-Alerts
blank image
Subscribe to our Email Alert or RSS feeds for the latest journal papers.

red arrow Connect with us
blank image
facebook   youtube

red arrow Interview with Kit Fairley
blank image
Hear Kit Fairley speak about what is sexual health.

 

Article << Previous     |     Next >>   Contents Vol 8(3)

Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Fiji

Sepehr N. Tabrizi A B H, Irwin Law C D, Eka Buadromo E, Matthew P. Stevens A, James Fong E, Josaia Samuela E, Mahomed Patel D, E. Kim Mulholland F G, Fiona M. Russell C and Suzanne M. Garland A B

A Regional WHO HPV Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Parkville, Vic. 3052, Australia.
B Department of Obstetrics and Gynaecology, University of Melbourne, The Royal Women’s Hospital and Murdoch Children’s Research Institute, Parkville, Vic. 3052, Australia.
C Centre for International Child Health, Murdoch Children’s Research Institute, Royal Children’s Hospital, Department of Paediatrics, University of Melbourne, Parkville, Vic. 3052, Australia.
D National Centre for Epidemiology and Population Health, Australian National University, Acton, ACT 0200, Australia.
E Ministry of Health, Suva, Fiji.
F Menzies School of Health Research, Department of Child Health, Darwin, NT 0811, Australia.
G London School of Hygiene and Tropical Medicine, University of London, WC1E 7HT, UK.
H Corresponding author. Email: Sepehr.tabrizi@thewomens.org.au

Sexual Health 8(3) 338-342 http://dx.doi.org/10.1071/SH10083
Submitted: 7 July 2010  Accepted: 24 September 2010   Published: 23 May 2011
 
PDF (143 KB) $25
 Export Citation
 Print
  
Abstract

Background: There is currently limited information about human papillomavirus (HPV) genotype distribution in women in the South Pacific region. This study’s objective was to determine HPV genotypes present in cervical cancer (CC) and precancers (cervical intraepithelial lesion (CIN) 3) in Fiji. Methods: Cross-sectional analysis evaluated archival CC and CIN3 biopsy samples from 296 women of Melanesian Fijian ethnicity (n = 182, 61.5%) and Indo-Fijian ethnicity (n = 114, 38.5%). HPV genotypes were evaluated using the INNO-LiPA assay in archival samples from CC (n = 174) and CIN3 (n = 122) among women in Fiji over a 5-year period from 2003 to 2007. Results: Overall, 99% of the specimens tested were HPV DNA-positive for high-risk genotypes, with detection rates of 100%, 97.4% and 100% in CIN3, squamous cell carcinoma (SCC) and adenosquamous carcinoma biopsies, respectively. Genotypes 16 and 18 were the most common (77%), followed by HPV 31 (4.3%). Genotype HPV 16 was the most common identified (59%) in CIN3 specimens, followed by HPV 31 (9%) and HPV 52 (6.6%). Multiple genotypes were detected in 12.5–33.3% of specimens, depending on the pathology. Conclusion: These results indicated that the two most prevalent CC-associated HPV genotypes in Fiji parallel those described in other regions worldwide, with genotype variations thereafter. These data suggest that the currently available bivalent and quadrivalent HPV vaccines could potentially reduce cervical cancers in Fiji by over 80% and reduce precancers by at least 60%.

Additional keywords:adenosquamous carcinoma, CIN3, South Pacific, squamous cell carcinoma.


References

[1]  Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
| CrossRef |

[2]  Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244–65.

[3]  Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, et al Human papillomavirus – the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 1996; 65: 601–6.
| CrossRef |

[4]  Muñoz N, Bosch FX. The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. Bull Pan Am Health Organ 1996; 30: 362–77.

[5]  Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518–27.
| CrossRef |

[6]  Muñoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, et al The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992; 52: 743–9.
| CrossRef |

[7]  Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85: 958–64.
| CrossRef |

[8]  Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–9.
| CrossRef |

[9]  Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70–9.
| CrossRef |

[10]  Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63–73.
| CrossRef |

[11]  de Sanjosé S, Diaz M, Castellsague X, Clifford G, Bruni L, Muñoz N, et al Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453–9.
| CrossRef |

[12]  Muñoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000; 19: 1–5.
| CrossRef |

[13]  Muñoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278–85.
| CrossRef |

[14]  Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination – implications for second generation vaccines. Vaccine 2008; 26: K62–7.
| CrossRef |

[15]  Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199: 926–35.
| CrossRef |

[16]  Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009; 199: 936–44.
| CrossRef |

[17]  2007 Census of Population and Housing. Fiji Islands: Bureau of Statistics; 2009. Available online at: http://www.statsfiji.gov.fj/Census2007/census07_index2.htm [verified August 2009].

[18]  WHO Statistical Information System (WHOSIS). World Health Organization: Geneva; 2009. Available online at: http://www.who.int/whosis/en/ [verified August 2009].

[19]  Prasad KFJ. The effectiveness of cervical cancer screening programme at Colonial War Memorial Hospital. Fiji Med J 2007; 26: 9–12.

[20]  Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928–43.
| CrossRef |

[21]  Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26: K1–16.
| CrossRef |

[22]  Cuschieri KS, Cubie HA, Whitley MW, Gilkison G, Arends MJ, Graham C, et al Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 2005; 58: 946–50.
| CrossRef |

[23]  Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.
| CrossRef |

[24]  Stevens MP, Tabrizi SN, Quinn MA, Garland SM. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 2006; 16: 1017–24.
| CrossRef |


   
Subscriber Login
Username:
Password:  

 
    
Legal & Privacy | Contact Us | Help

CSIRO

© CSIRO 1996-2013